Treatment withcompound 35 decreased p-IκBα and reducedp65 levels in the cellular models, which is associated with inhibitionof NF-κB transcriptional activity, leading to cancer cell death.As illustrated in Figure 5, the NF-κB family of transcription factors is a masterregulator of immune development, immune responses, inflammation, andcancer. This evidence concerns the gene NFKB1 and cancer.